Home > Press > Harris & Harris Group Notes $27 Million Financing of Mersana Therapeutics
 |
Abstract:
Harris & Harris Group, Inc. (NASDAQ: TINY), an early-stage, active investor in transformative nanotechnology companies, notes the announcement by Mersana Therapeutics, Inc., of the close of a $27 million Series A-1 financing led by a new investor, New Enterprise Associates. Harris & Harris Group invested in this round of financing. Participation in the round also included another new investor, Pfizer Venture Investments, and Mersana's other existing investors, Fidelity Biosciences, ProQuest Investments, and Rho Ventures.
Harris & Harris Group Notes $27 Million Financing of Mersana Therapeutics
New York, NY | Posted on July 31st, 2012Mersana is a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and its pipeline of small molecule Fleximer conjugates. The proceeds from this financing will be used to advance Mersana's Fleximer-based ADC technology and to generate a pipeline of proprietary next-generation ADCs. The full press release can be viewed at www.prnewswire.com/news-releases/mersana-therapeutics-raises-27m-to-advance-fleximer-antibody-drug-conjugates-164408226.html.
####
About Harris & Harris Group, Inc.
Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com.
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites www.HHVC.com and www.prnewswire.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.
For more information, please click here
Copyright © Harris & Harris Group, Inc.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
| Related News Press |
News and information
Application of air-sensitive semiconductors in nanoelectronics: 2-D semiconductor gallium selenide in encapsulated nanoelectronic devices September 22nd, 2017
Researchers set time limit for ultrafast perovskite solar cells September 22nd, 2017
DNA triggers shape-shifting in hydrogels, opening a new way to make 'soft robots' September 21st, 2017
Physicists develop new recipes for design of fast single-photon gun Physicists develop high-speed single-photon sources for quantum computers of the future September 21st, 2017
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017
Forge Nano 2017: 1st Quarter Media Update April 20th, 2017
Caught on camera -- chemical reactions 'filmed' at the single-molecule level March 22nd, 2017
Investments/IPO's/Splits
Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017
Nanometrics Announces Upcoming Investor Events August 3rd, 2017
Nanomedicine
Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017
Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017
Graphene based terahertz absorbers: Printable graphene inks enable ultrafast lasers in the terahertz range September 13th, 2017
Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017
Announcements
Application of air-sensitive semiconductors in nanoelectronics: 2-D semiconductor gallium selenide in encapsulated nanoelectronic devices September 22nd, 2017
Researchers set time limit for ultrafast perovskite solar cells September 22nd, 2017
DNA triggers shape-shifting in hydrogels, opening a new way to make 'soft robots' September 21st, 2017
Physicists develop new recipes for design of fast single-photon gun Physicists develop high-speed single-photon sources for quantum computers of the future September 21st, 2017
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
University Technology Transfer & Patents
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||